Excelsior Medical Co., Ltd. (4104.TW)
TWD 86.1
(-0.35%)
TWD 86.1
(-0.35%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 968.55 Million TWD | -11.33% |
| 2022 | 1.09 Billion TWD | 12.35% |
| 2021 | 972.18 Million TWD | -3.79% |
| 2020 | 1.01 Billion TWD | 8.08% |
| 2019 | 934.95 Million TWD | 22.55% |
| 2018 | 591.19 Million TWD | 13.73% |
| 2017 | 563.26 Million TWD | -6.11% |
| 2016 | 474.99 Million TWD | 0.94% |
| 2015 | 707.82 Million TWD | 13.2% |
| 2014 | 459.25 Million TWD | 7.93% |
| 2013 | 579.36 Million TWD | 3.39% |
| 2012 | 560.35 Million TWD | -19.01% |
| 2011 | 678.24 Million TWD | -1.15% |
| 2010 | 585.59 Million TWD | 27.73% |
| 2009 | 524.44 Million TWD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 240.41 Million TWD | 5.06% |
| 2024 Q1 | 228.82 Million TWD | -13.49% |
| 2023 Q4 | 264.51 Million TWD | -19.87% |
| 2023 Q2 | 324.66 Million TWD | -4.83% |
| 2023 Q3 | 330.11 Million TWD | 1.68% |
| 2023 FY | - TWD | -11.33% |
| 2023 Q1 | 341.14 Million TWD | 27.79% |
| 2022 Q2 | 251.03 Million TWD | -5.25% |
| 2022 Q3 | 309.36 Million TWD | 23.24% |
| 2022 Q4 | 266.94 Million TWD | -13.71% |
| 2022 FY | - TWD | 12.35% |
| 2022 Q1 | 264.95 Million TWD | -8.69% |
| 2021 FY | - TWD | -3.79% |
| 2021 Q3 | 253.32 Million TWD | 26.83% |
| 2021 Q4 | 290.17 Million TWD | 14.55% |
| 2021 Q1 | 255.82 Million TWD | 2.51% |
| 2021 Q2 | 199.73 Million TWD | -21.93% |
| 2020 Q2 | 256.63 Million TWD | -3.62% |
| 2020 Q1 | 266.26 Million TWD | 21.44% |
| 2020 Q3 | 238.07 Million TWD | -7.23% |
| 2020 Q4 | 249.55 Million TWD | 4.82% |
| 2020 FY | - TWD | 8.08% |
| 2019 Q2 | 242.13 Million TWD | 2.28% |
| 2019 Q4 | 219.25 Million TWD | -7.42% |
| 2019 FY | - TWD | 22.55% |
| 2019 Q1 | 236.73 Million TWD | 24.39% |
| 2019 Q3 | 236.82 Million TWD | -2.19% |
| 2018 Q4 | 190.32 Million TWD | -0.14% |
| 2018 FY | - TWD | 13.73% |
| 2018 Q3 | 190.58 Million TWD | -6.81% |
| 2018 Q2 | 204.49 Million TWD | 15.19% |
| 2018 Q1 | 177.53 Million TWD | 14.91% |
| 2017 Q3 | 148.35 Million TWD | -7.33% |
| 2017 Q1 | 207.89 Million TWD | 33.18% |
| 2017 Q2 | 160.08 Million TWD | -23.0% |
| 2017 FY | - TWD | -6.11% |
| 2017 Q4 | 154.5 Million TWD | 4.14% |
| 2016 Q1 | 209.05 Million TWD | 11.9% |
| 2016 Q2 | 179.43 Million TWD | -14.17% |
| 2016 Q3 | 169.9 Million TWD | -5.31% |
| 2016 Q4 | 156.1 Million TWD | -8.12% |
| 2016 FY | - TWD | 0.94% |
| 2015 Q2 | 194.49 Million TWD | 20.0% |
| 2015 Q1 | 162.07 Million TWD | 22.23% |
| 2015 FY | - TWD | 13.2% |
| 2015 Q3 | 164.43 Million TWD | -15.46% |
| 2015 Q4 | 186.81 Million TWD | 13.61% |
| 2014 Q4 | 132.6 Million TWD | -16.93% |
| 2014 Q3 | 159.62 Million TWD | -4.02% |
| 2014 Q1 | 166.77 Million TWD | 71.78% |
| 2014 FY | - TWD | 7.93% |
| 2014 Q2 | 166.3 Million TWD | -0.28% |
| 2013 Q3 | 153.81 Million TWD | -26.22% |
| 2013 Q1 | 119.96 Million TWD | 79.57% |
| 2013 FY | - TWD | 3.39% |
| 2013 Q4 | 97.08 Million TWD | -36.88% |
| 2013 Q2 | 208.49 Million TWD | 73.8% |
| 2012 Q4 | 66.8 Million TWD | -61.41% |
| 2012 Q3 | 173.12 Million TWD | -0.26% |
| 2012 Q2 | 173.56 Million TWD | -5.1% |
| 2012 FY | - TWD | -19.01% |
| 2012 Q1 | 182.89 Million TWD | 11.28% |
| 2011 Q2 | 181.84 Million TWD | -1.08% |
| 2011 Q1 | 183.82 Million TWD | 34.69% |
| 2011 FY | - TWD | -1.15% |
| 2011 Q4 | 164.35 Million TWD | 1.55% |
| 2011 Q3 | 161.85 Million TWD | -10.99% |
| 2010 Q3 | 203.35 Million TWD | 7.7% |
| 2010 FY | - TWD | 27.73% |
| 2010 Q4 | 136.48 Million TWD | -32.88% |
| 2010 Q1 | 171.3 Million TWD | 0.0% |
| 2010 Q2 | 188.81 Million TWD | 10.22% |
| 2009 FY | - TWD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Apex Medical Corp. | 318.12 Million TWD | -204.46% |
| OK Biotech Co., Ltd. | 87.24 Million TWD | -1010.169% |
| Applied BioCode Corporation | -98.59 Million TWD | 1082.398% |